Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta vulgaris pollen is a non-standardized allergenic extract derived from the pollen of the sugar beet plant (*Beta vulgaris*). Developed and manufactured by Greer Laboratories, it is primarily used as a diagnostic tool for skin testing to identify allergic sensitization in individuals, particularly those with occupational exposure in sugar beet seed production. It is also indicated for allergen immunotherapy to treat patients with a documented history of immediate hypersensitivity to sugar beet pollen. The extract contains specific allergen proteins such as Beta v 1 and Beta v 2. It is available as an injectable solution for intradermal, percutaneous, or subcutaneous administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta vulgaris pollen.